Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9─GM2 to treat GM2 gangliosidoses

Written by

taufiqkharadi

in

,
Andelyn Biosciences partners with Queen's University to develop and manufacture gene therapy AAV9─GM2 to treat GM2 gangliosidoses
Image credit: Pharma Biz
Source: Pharma Biz

Andelyn Biosciences partners with Queen's University to develop and manufacture gene therapy AAV9─GM2 to treat GM2 gangliosidoses

Andelyn Biosciences Inc, a leading patient─focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Queen's University to develop and manufacture AAV9─GM2

Key Points

  • Andelyn Biosciences Inc, a leading patient─focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Queen's University to develop and manufacture AAV9─GM2

Published: August 20, 2026 5:30 am

Source: Pharma Biz

Read the original article →

More posts